Table 1. Characteristics of study participants in a randomized, crossover trial of 2010–11 inactivated, trivalent influenza vaccine vs. placebo.
| First injection: TIV* | First injection: Placebo* | Total group | |
|---|---|---|---|
| Male |
48 (29.4%) |
48 (29.4%) |
96 (29.4%) |
| Age, years, mean (± SD) |
41.7 (11.4) |
41.5 (11.2) |
41.6 (11.3) |
| BMI, mean (± SD) |
26.9 (5.3) |
26.8 (5.5) |
26.8 (5.4) |
| Caucasian/white |
145 (89.0%) |
145 (89.0%) |
290 (89.0%) |
| Chronic health condition** |
89 (54.6%) |
87 (53.4%) |
176 (54.0%) |
| Previous TIV |
149 (91.4%) |
144 (88.3%) |
293 (89.9%) |
| Total number | 163 | 163 | 326 |
*
Opposite assignment applied to second (crossover) injections; **Refers to any ongoing medical condition, not just those posing increased risk with influenza.